ANO1-IN-2 (Compound 10q) is a potent and selective ANO1 channel blocker. It exhibits an IC50 value of 1.75 μM against ANO1 and 7.43 μM against ANO2. Furthermore, ANO1-IN-2 demonstrates significant anti-proliferative activity in glioblastoma cells [1].
4-Amino-5-cyano-1-(2-b-C-methyl-b-D-ribofuranosyl)-7H-pyrrolo[2.3-d]pyrimidine is a Nucleoside Derivative - 7-Deaza-purine nucleoside; 2'-Modified nucleoside.
4-Amino-6-bromo-5-cyano-1-(2,3,5-tri-O-benzoyl-b-D-ribofuranosyl)-7H-pyrrolo[2.3-d]pyrimidine is a Nucleoside Derivative - 7-Deaza-purine nucleoside, 8-Modified-purine nucleoside, Halo-nucleoside; Scaffold and Template.
4-Amino-6-bromo-5-cyano-1-(beta-D-ribofuranosyl)-7H-pyrrolo[2.3-d]pyrimidine is a Nucleoside Derivative - 7-Deaza-purine nucleoside, 8-Modified-purine nucleoside, Halo-nucleoside; Scaffold and Template.
DFBTA is a highly effective and orally active inhibitor of ANO1, specifically the calcium-activated chloride channel anoctamin-1. It exhibits potent inhibitory activity, with an IC 50 of 24 nM. Notably, DFBTA demonstrates significant analgesic efficacy in treating inflammatory pain [1].